Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.48 -6.4%	$2.48	$1.84 ▼ $5.59	$86.02M	1.49	188,050 shs	141,188 shs
FBIO Fortress Biotech	$1.66 -4.6%	$1.63	$1.33 ▼ $2.89	$49.09M	1.85	406,783 shs	104,199 shs
IRWD Ironwood Pharmaceuticals	$0.65 -5.1%	$1.10	$0.59 ▼ $7.11	$105.01M	0.37	2.52 million shs	2.43 million shs
SGMO Sangamo Therapeutics	$0.44 -4.8%	$0.75	$0.30 ▼ $3.18	$100.39M	1.46	8.71 million shs	5.88 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-6.42%	+4.20%	+14.29%	-26.84%	-50.50%
FBIO Fortress Biotech	-4.60%	-3.77%	+5.73%	-5.68%	-5.68%
IRWD Ironwood Pharmaceuticals	-5.14%	-18.06%	+0.17%	-67.71%	-90.21%
SGMO Sangamo Therapeutics	-4.78%	-32.20%	-41.64%	-62.56%	-22.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	2.0931 of 5 stars	3.8	0.0	0.0	3.2	1.7	0.6
FBIO Fortress Biotech	1.9557 of 5 stars	3.5	0.0	0.0	1.8	3.3	0.6
IRWD Ironwood Pharmaceuticals	4.5242 of 5 stars	4.1	4.0	3.4	1.8	0.8	1.9
SGMO Sangamo Therapeutics	1.8842 of 5 stars	3.3	1.0	0.0	2.3	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	477.96% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	1,165.06% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	637.03% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	927.40% Upside

Current Analyst Ratings Breakdown

Latest FBIO, SGMO, IRWD, and ACHV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	SGMO Sangamo Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $5.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00
4/15/2025	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $0.70
4/14/2025	IRWD Ironwood Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$3.00 ➝ $1.00
4/14/2025	IRWD Ironwood Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/7/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/18/2025	SGMO Sangamo Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$2.00 ➝ $2.00
3/11/2025	FBIO Fortress Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $16.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	($0.07) per share	N/A
FBIO Fortress Biotech	$57.68M	0.85	N/A	N/A	$0.10 per share	16.60
IRWD Ironwood Pharmaceuticals	$317.68M	0.33	N/A	N/A	($2.21) per share	-0.29
SGMO Sangamo Therapeutics	$57.80M	1.74	$0.01 per share	30.42	$0.47 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$29.82M	-$1.23	N/A	N/A	N/A	N/A	-108.30%	-65.20%	N/A
FBIO Fortress Biotech	-$60.64M	-$2.78	N/A	N/A	N/A	-84.53%	N/A	-34.93%	5/21/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	-$1.00B	-$0.20	N/A	2.60	N/A	-0.65%	-0.96%	0.74%	N/A
SGMO Sangamo Therapeutics	-$257.83M	-$0.39	N/A	N/A	N/A	-257.87%	-264.16%	-107.24%	N/A

Latest FBIO, SGMO, IRWD, and ACHV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	FBIO Fortress Biotech	-$0.44	N/A	N/A	N/A	$11.62 million	N/A
5/13/2025	Q1 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
5/12/2025	Q1 2025	SGMO Sangamo Therapeutics	-$0.11	-$0.14	-$0.03	-$0.14	$7.90 million	$6.44 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
3/31/2025	Q4 2024	FBIO Fortress Biotech	-$0.79	-$0.26	+$0.53	-$0.26	$16.30 million	$15.12 million
3/17/2025	Q4 2024	SGMO Sangamo Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	$11.70 million	$7.55 million
3/11/2025	Q4 2024	ACHV Achieve Life Sciences	-$0.30	-$0.36	-$0.06	-$0.36	N/A	N/A
2/27/2025	Q4 2024	IRWD Ironwood Pharmaceuticals	$0.10	$0.02	-$0.08	$0.02	$93.85 million	$90.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.31	6.78	6.78
FBIO Fortress Biotech	N/A	1.23	1.06
IRWD Ironwood Pharmaceuticals	N/A	3.62	3.62
SGMO Sangamo Therapeutics	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
FBIO Fortress Biotech	96.51%
IRWD Ironwood Pharmaceuticals	N/A
SGMO Sangamo Therapeutics	56.93%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	2.00%
FBIO Fortress Biotech	33.40%
IRWD Ironwood Pharmaceuticals	12.90%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.70 million	Optionable
FBIO Fortress Biotech	170	29.57 million	18.39 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.81 million	139.38 million	Optionable
SGMO Sangamo Therapeutics	480	229.19 million	202.81 million	Optionable

FBIO, SGMO, IRWD, and ACHV Headlines

Recent News About These Companies

Sangamo Therapeutics Target of Unusually Large Options Trading (NASDAQ:SGMO)

May 15 at 1:21 AM | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results

May 14 at 5:58 PM | marketbeat.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12 at 10:06 PM | seekingalpha.com

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 12 at 7:17 PM | finance.yahoo.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 12 at 6:55 PM | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12 at 6:26 PM | businesswire.com

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12 at 6:23 PM | businesswire.com

Sangamo Therapeutics Q1 2025 Earnings Preview

May 12 at 1:36 AM | msn.com

Why Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%

May 10, 2025 | aaii.com

Schonfeld Strategic Advisors LLC Purchases Shares of 1,709,615 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

May 8, 2025 | marketbeat.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.17 Average Price Target from Analysts

May 8, 2025 | americanbankingnews.com

Sangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene Therapy

May 7, 2025 | precisionmedicineonline.com

Sangamo Therapeutics (SGMO) Projected to Post Quarterly Earnings on Thursday

May 7, 2025 | americanbankingnews.com

Marshall Wace LLP Has $344,000 Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

May 7, 2025 | marketbeat.com

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 7, 2025 | finance.yahoo.com

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025 | businesswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 6, 2025 | marketbeat.com

740,000 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by Acuta Capital Partners LLC

May 4, 2025 | marketbeat.com

Boothbay Fund Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

May 3, 2025 | marketbeat.com

Sangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

May 1, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, SGMO, IRWD, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.48 -0.17 (-6.42%)

As of 05/14/2025 04:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Fortress Biotech NASDAQ:FBIO

$1.66 -0.08 (-4.60%)

As of 05/14/2025 04:00 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.65 -0.04 (-5.14%)

As of 05/14/2025 04:00 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Sangamo Therapeutics NASDAQ:SGMO

$0.44 -0.02 (-4.78%)

As of 05/14/2025 04:00 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time